Skip to main content
. 2019 Nov 15;8(11):1990. doi: 10.3390/jcm8111990

Figure 3.

Figure 3

Effect of platelet aggregation with addition of rivaroxaban, PAR-1 and PAR-4 inhibitor to human platelet rich plasma (PRP) in TG. Representative TG curves in PRP or PRP after aggregation (agPRP) triggered with 2 µg/mL of collagen with and without addition or 50 ng/mL of rivaroxaban and inhibition of PAR-1 with vorapaxar (100 ng/mL) (A), inhibition of PAR-4 with BMS 896120 (1 µg/mL) (B) or a combination of both inhibitor (C). Lag time after addition of vorapaxar (D) BMS 986120 (E) or a combination of both inhibitor (F). Velocity after addition of vorapaxar (G) BMS 986120 (H) or a combination of both inhibitor (I). Results are presented as median (min-max). * p < 0.05, vs. PRP; # p < 0.05, ## p < 0.01, vs. agPRP, n = 4–5 per group.